PARSIPPANY, N.J.--(BUSINESS WIRE)-- Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.
The patent, titled “Treating Neoplasms with Neurotoxin,” outlines the use of botulinum toxin around the cancer cell to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites.
Toxcure plans to advance the clinical use of neurotoxins in the field of oncology based on data recently generated in preclinical studies comparing tumors treated with neurotoxin plus chemotherapy to tumors treated with neurotoxin alone. These data demonstrate a statistically significant reduction in tumor growth in the neurotoxin-plus-chemotherapy group, as well as a trend toward reduced growth in the neurotoxin-treated group. In addition, Toxcure has additional patent applications for neurotoxin use to enhance cellular and humoral immunologic functions to support cancer cell death or to prevent the spread of cancer cells.
“The use of a neurotoxin as neoadjuvant therapy has significant application to a number of cancers, and our preliminary data with botulinum toxin is very promising in the treatment of solid tumors,” stated Toxcure President and Chief Medical Officer, Dr. Christopher Shaari. “In addition, this patent supports our corporate strategy of seeking partners to further develop this potential treatment approach.”
Toxcure is an emerging specialty pharmaceutical company with a primary focus on developing products which improve treatment and patient outcomes in oncology. The company’s founders have dedicated years of research to advancing the use of neurotoxins in the treatment of tumors. Toxcure is advancing the development of botulinum toxin as an adjuvant to chemotherapy to reduce the growth of solid tumors. Additional information about Toxcure is available at www.toxcure.com.
This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.
Taunia Markvicka, 908-930-4995
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Research Science